2 active not recruiting, 2 recruiting, 1 not yet recruiting, 1 withdrawn. 5 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow Ali Rezai: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Intensity Focused Ultrasound for Parkinson's Disease LIFU Neuromodulation - Parkinson Disease | Not applicable | Not yet recruiting | Ali Rezai | 15 | 2026-12-01 | 2026-02-17 |
| Low Intensity Focused Ultrasound for Binge Eating Disorder LIFU Neuromodulation - Binge-Eating Disorder | Not applicable | Active not recruiting | Ali Rezai | 15 | 2024-10-31 | 2025-12-18 |
| LIFU for Treatment for Refractory Opioid Use Disorder Low Intensity Focussed Ultrasound - Opioid Use Disorder | Not applicable | Recruiting | Ali Rezai | 34 | 2024-05-09 | 2026-02-17 |
| Low-Intensity Focused Ultrasound (LIFU) Neuromodulation low intensity focused ultrasound (LIFU) - Alzheimer Disease | Not applicable | Recruiting | Ali Rezai | 15 | 2023-10-12 | 2025-11-24 |
| Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy Aducanumab, Exablate Model 4000 Type 2, Lecanemab - Mild Cognitive Impairment, Alzheimer Disease 1 | Early Phase 1 | Active not recruiting | Ali Rezai | 15 | 2022-07-14 | 2026-01-22 |
| Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease TMS stimulation with X-Torp task, TMS-Stimulation with MindMotion Go, TMS-Sham with X-Torp task - Alzheimer Disease | Not applicable | Withdrawn | Ali Rezai | 2019-10-03 | 2023-08-14 |
Alzheimer Disease (2) · Alzheimer disease type 1 (1) · Binge-Eating Disorder (1) · Cognitive Dysfunction (1) · Opioid-Related Disorders (1) · Parkinson Disease (1)
aducanumab (1) · lecanemab (1)
United States (5)
Marc Haut, PhD (1) · Victor Finomore, PhD (1)